One of NASCAR’s most successful pipelines for developing young drivers is coming to an end. Joe Gibbs Racing will shut down ...
On March 12, 2026, the company announced the start of the program for a total amount of €540 million, of which €40 million to cover commitments under the Group’s share-based compensation plans and ...
REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the alliance, along with a long-acting IL-4xIL-13 bispecific and two other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results